The Hidden Crisis After a Life-Saving Heart Stent
Every year, more than 8 million people worldwide die from acute myocardial infarction—what most of us call a heart attack. Roughly one-third of these deadly cases are ST-segment elevation myocardial infarction, or STEMI, the most severe form of heart attack you can experience. If you or a loved one has ever raced to an emergency room with crushing chest pain, shortness of breath, and cold sweats, you know how terrifying this medical emergency truly is.
For decades, doctors have relied on one gold-standard treatment to pull STEMI patients back from the brink: primary percutaneous coronary intervention, shortened to pPCI. In plain language, this is the emergency stent procedure that blasts open fully blocked heart arteries and restores blood flow to oxygen-starved heart muscle. When done within the critical 12-hour symptom window, pPCI saves countless lives. But here’s a devastating secret modern cardiology cannot ignore: even with fast, successful stent placement, the danger does not disappear once blood flows again.
Clinical data tells a grim story: after pPCI, nearly 4% of STEMI patients die during their hospital stay. One full year after discharge, that death rate jumps to 10%. Among everyone who survives the initial heart attack, around 1 in 5 will eventually develop heart failure—a chronic, lifelong condition where the heart becomes too weak to pump blood efficiently through the body. Millions of heart attack survivors face fatigue, breathlessness with simple movement, repeated hospital visits, and shortened lifespans, all despite receiving state-of-the-art emergency stent care.
Why does this happen? The answer lies in a cruel medical paradox: restoring blood flow to damaged heart tissue creates new damage, called myocardial ischemia-reperfusion injury, or I/RI for short. Imagine a garden hose left crimped shut for hours, cutting off water to your plants. When you release the crimp, rushing water surges through the line—powerful enough to tear fragile roots and flood delicate leaves. Your heart muscle faces this exact same trauma when blocked arteries reopen during a stent procedure. The sudden rush of oxygen-rich blood triggers overwhelming inflammation, toxic chemical buildup, and cell death deep inside the heart wall. This hidden secondary injury sets off a chain reaction that warps the heart’s shape, weakens its pumping power, and paves the way for heart failure months or years later.
Cardiologists have spent years hunting for a simple, affordable drug to block this harmful chain reaction and protect heart muscle after stents. Now, a large-scale Chinese clinical trial led by Shanghai Zhongshan Hospital is testing a surprising candidate: montelukast, a cheap, widely available pill most people know as a daily asthma and allergy medication. The trial (registered under ID ) asks a revolutionary question: can a drug designed to calm inflamed airways also shield the heart from life-altering damage after a severe heart attack? This article breaks down the science, the trial design, and the real-world hope this repurposed medicine brings to millions of heart attack survivors—no confusing medical jargon required.
Chapter 1: Understanding STEMI, Stents, and the Silent Heart Damage That Follows
Before we dive into montelukast, let’s unpack exactly what a STEMI heart attack is, how pPCI works, and why reperfusion injury ruins long-term recovery for so many patients.
What Is a STEMI Heart Attack?
Your heart runs on three thin coronary arteries that carry oxygen and nutrients to hardworking heart muscle cells. Over years, cholesterol, fat, and inflammatory cells build up inside artery walls, forming sticky plaques. When one plaque suddenly ruptures, your body’s emergency clotting system springs into action, piling platelets and proteins on the rupture site to stop internal bleeding. The resulting blood clot can fully plug the artery shut, cutting off oxygen to a large section of heart muscle. This complete blockage creates a STEMI, identifiable by a distinctive spike (ST elevation) on an electrocardiogram (ECG) readout.
Anterior STEMI—the group targeted in this trial—blocks the left anterior descending artery, the “widow-maker” vessel that feeds the heart’s front pumping chamber. Damage here hits the heart’s main pumping muscle hardest, creating the highest risk of permanent heart weakness after recovery. Without instant treatment, heart muscle cells die off rapidly, turning healthy contractile tissue into stiff, scarred tissue that cannot squeeze blood properly.
pPCI: The Life-Saving Stent Procedure
Primary PCI is the emergency stent operation that stops immediate heart death. Doctors thread a tiny tube through an arm or leg blood vessel up to the blocked heart artery, inflate a small balloon to crush the clot and plaque, then place a metal mesh stent to hold the artery open permanently. This restores blood flow within minutes, halting mass heart cell death and cutting immediate mortality drastically.
For decades, the medical community celebrated pPCI as a near-perfect cure for STEMI. But researchers slowly realized the procedure only solves half the problem: it fixes the blocked pipe, not the inflammatory chaos unleashed the second blood returns to starved heart tissue. That chaos is ischemia-reperfusion injury.
Reperfusion Injury: The Heart’s Hidden Post-Stent Enemy
Let’s simplify I/RI without textbook terminology. When heart cells lack oxygen for hours during a STEMI, they shift into survival mode, breaking down energy stores and filling with harmful waste chemicals. When oxygen floods back via the stent-opened artery, these trapped toxic compounds erupt across heart tissue, triggering three destructive processes:
- Massive inflammation: Immune cells rush to the injured area, releasing inflammatory molecules that burn healthy heart cells surrounding the dead infarct zone. One key harmful molecule here is leukotriene C4, or LTC4, a chemical that ramps up inflammation and tissue damage.
- Neutrophil “net traps”: Immune cells release sticky web-like structures (NETs) that clog tiny heart capillaries, blocking oxygen delivery even in arteries that the stent opened.
- Permanent heart shape distortion (left ventricular remodeling): Damaged heart walls stretch and thin over weeks and months. The heart’s natural oval shape balloons into a round, floppy sack that cannot pump blood efficiently—this is left ventricular remodeling, the main driver of post-heart attack heart failure.
Scientists at Shanghai Zhongshan Hospital discovered a critical link in this damage chain: patients with higher LTC4 levels right after their STEMI stent surgery are far more likely to develop this irreversible heart remodeling and suffer future cardiovascular complications. LTC4 acts as a chemical “damage signal” that fuels every step of reperfusion injury. If doctors could safely block LTC4’s activity right after a heart attack, they might halt this entire harmful cascade before permanent heart weakness sets in. That is where montelukast enters the picture.
Chapter 2: Montelukast—The Asthma Pill With Unexpected Heart Protective Powers
If you or your child has mild asthma or seasonal allergies, you almost certainly recognize montelukast. Sold under brand names like Singulair, this small daily tablet has been prescribed globally for over 20 years to calm swollen, tight airways by blocking leukotriene molecules—exactly the same family of inflammatory chemicals that damage heart tissue after STEMI.
How Montelukast Works for Asthma (and How This Translates to Heart Care)
When allergies or asthma flare up, your body releases cysteinyl leukotrienes, chemicals that inflame airway lining, tighten lung muscles, and trigger coughing and wheezing. Montelukast is a leukotriene receptor antagonist: it locks onto the cell receptors that leukotrienes bind to, blocking these inflammatory molecules from activating damage signals. For asthma patients, this eases airway swelling overnight with a single 10mg daily pill.
Over the past decade, cardiovascular researchers noticed a striking coincidence: patients who took montelukast long-term for asthma had significantly fewer major heart complications, including heart attacks, strokes, and heart failure, compared to asthma patients on other allergy medications. This observation sparked a wave of animal and lab studies testing whether montelukast could directly protect damaged heart muscle.
Preclinical Proof: Montelukast Shields Hearts in Lab Models
Laboratory research using heart attack mouse models delivered groundbreaking results: when researchers gave montelukast to mice immediately after induced heart attacks, the treated animals had far smaller areas of dead heart tissue, less heart wall stretching, and stronger pumping function months later. The drug blocked the LTC4-driven inflammatory pathway that fuels reperfusion injury, stopping NET formation and limiting toxic inflammation spreading across healthy heart tissue.
A pooled analysis combining 26 separate animal experiments and two early human clinical studies confirmed this promising trend: montelukast consistently reduced markers of permanent heart damage and adverse cardiac remodeling across all test groups. Unlike many experimental heart drugs, montelukast has a decades-long safety record in millions of patients, with minimal side effects when taken at standard daily doses. This “drug repurposing” approach—using an already approved, low-cost medication for a brand-new medical condition—cuts years off drug development timelines and eliminates the massive financial risk of developing a brand-new heart pill from scratch.
The Core Trial Hypothesis
Drawing on all this preclinical and observational evidence, the research team at Shanghai Zhongshan Hospital formed a clear, testable theory: For patients who suffer an anterior STEMI and receive emergency pPCI, adding daily montelukast to their standard heart medication routine will reduce reperfusion injury, slow or stop harmful left ventricular remodeling, preserve heart pumping function, and lower long-term risks of heart failure and cardiovascular death. The trial exists to prove whether this theory holds true in real human heart attack survivors.
Chapter 3: Inside the New Montelukast STEMI Clinical Trial (Simplified for General Readers)
This section covers the trial structure, participant rules, treatment plan, and primary measurement goal—avoiding dense regulatory jargon while highlighting why the study design makes its results reliable and trustworthy for patients worldwide.
Basic Trial Overview
- Official Name: Clinical Therapeutic Efficacy of Montelukast on Anterior STEMI Patients With Primary Percutaneous Coronary Intervention
- Lead Institution: Shanghai Zhongshan Hospital, Fudan University (China)
- Trial Type: Phase 3 randomized, triple-blinded parallel-group intervention study
- Estimated Total Participants: 512 adult heart attack patients
- Recruitment Status: Currently enrolling participants across 12 major Chinese hospitals (Shanghai, Dalian, Fuzhou, Guangzhou, Harbin, Hefei, Changsha, Shenyang, Wenzhou)
- Estimated Timeline: Recruitment starts February 1, 2026; primary data collection finishes February 1, 2027; full trial completion May 1, 2027 What “Randomized Triple-Blinded” Means for Fair Results
High-quality clinical trials rely on blinding to eliminate bias, and this study uses the strictest triple-blind design:
- Participants: No patient knows whether they swallow montelukast or a dummy placebo tablet each day.
- Care providers: Nurses, ward doctors, and cardiologists managing the patient cannot view group assignments.
- Investigators: The research team analyzing final scan data and health outcomes also remains unaware of who received active drug vs. placebo.
All patients are randomly sorted into two equal groups by a computer algorithm:
- Experimental Group: Montelukast 10mg oral tablet, once daily for 3 months, alongside all standard post-heart attack medications (blood thinners, statins, blood pressure drugs, etc.)
- Control Placebo Group: Identical-looking dummy pill, 1 tablet daily for 3 months, paired with the exact same standard heart treatment as the montelukast group.
The placebo tablet matches the real drug in size, shape, and taste, so no one can guess their treatment group based on appearance or side effects.
Who Can Join the Trial (Inclusion Rules)
To qualify for enrollment, patients must meet four simple core requirements:
- Age between 18 and 75 years old (adult and older adult populations)
- Confirmed anterior STEMI diagnosis, scheduled to undergo emergency pPCI within the 12-hour symptom window
- Chest pain and heart attack symptoms began less than 12 hours before hospital arrival
- Voluntarily sign informed consent paperwork, agreeing to all study follow-up visits and heart imaging scans Trial Transparency and Data Sharing
The study team commits to full individual participant data (IPD) sharing once the trial concludes. All raw patient health records, trial protocols, statistical analysis plans, consent forms, and final clinical study reports will be made available to independent researchers worldwide, eliminating hidden data bias and allowing global cardiologists to validate the results independently. This open-data policy sets a high standard for cardiovascular clinical research in Asia. Chapter 4: Why This Trial Matters for Every Heart Attack Patient Worldwide
This research carries transformative potential for global heart health care, with three massive real-world benefits that extend far beyond the hospitals running the study. - A Low-Cost, Widely Accessible Heart Protection Tool
Unlike brand-new experimental heart drugs that cost hundreds or thousands of dollars per month, montelukast is a generic medication available at low cost across every country. It requires no injections, no hospital monitoring, and only a single daily oral pill—an incredibly simple treatment to add to standard post-heart attack care. If the trial confirms its heart-protective effects, doctors worldwide can immediately prescribe montelukast to STEMI patients without waiting for lengthy new drug approval pipelines. This accessibility makes it a game-changer for low- and middle-income regions where expensive novel cardiac therapies remain out of reach for most patients. - Closing the Critical Gap in Post-Stent Heart Care
Current standard heart attack treatment focuses almost entirely on preventing repeat blood clots: blood thinners, cholesterol-lowering statins, and blood pressure medication all target plaque buildup and clot formation. No widely used daily oral drug directly addresses reperfusion injury and post-infarct heart remodeling—the silent damage that drives heart failure years after stenting. Montelukast would fill this major treatment gap, adding a dedicated anti-inflammatory cardioprotective layer to routine STEMI recovery plans. - Pioneering Drug Repurposing for Cardiovascular Disease
Drug repurposing—finding new uses for old, safe medicines—represents the future of affordable medical innovation. Developing one brand-new heart drug can cost billions of dollars and take over a decade of testing. Montelukast’s established safety profile cuts this timeline down to just a few years of Phase 3 trial data. If this trial succeeds, it will inspire researchers to test dozens of other common, cheap medications for hidden heart-protective effects, unlocking affordable treatment options for millions living with heart disease globally. Chapter 5: What Comes Next? Realistic Expectations for Trial Results
No clinical study carries guaranteed positive outcomes, and it is critical to frame balanced expectations for this montelukast STEMI trial. Best-Case Scenario
If the montelukast group shows a statistically significant reduction in left ventricular remodeling at six months, the research team will publish full results in top international cardiology journals. Cardiology guidelines groups will begin reviewing montelukast as a recommended add-on therapy for anterior STEMI patients receiving pPCI. Hospitals worldwide will start offering montelukast prescriptions to heart attack survivors as standard recovery care, lowering long-term heart failure rates and reducing repeat hospitalizations for cardiovascular complications. Neutral or Negative Outcome Possibility
It remains possible that daily montelukast delivers no measurable reduction in heart remodeling for STEMI patients. Even if the primary endpoint shows no difference between treatment and placebo groups, the trial will still generate valuable scientific data: it will confirm that blocking LTC4 alone is insufficient to stop reperfusion injury in human patients, guiding researchers toward other inflammatory targets for future heart protection therapies. Every well-designed clinical trial—whether positive or negative—moves cardiovascular science forward by eliminating unhelpful treatment paths. Long-Term Follow-Up After Trial Completion
While the formal drug treatment period lasts only three months, researchers will track participants’ cardiovascular health for years after the trial ends, documenting long-term rates of heart failure, repeat heart attacks, stroke, and all-cause mortality. This extended real-world follow-up will reveal whether short-term montelukast treatment delivers lasting heart protection, or if longer daily dosing may be required for maximum benefits. Conclusion: A Simple Asthma Pill Could Rewrite Heart Attack Recovery Standards
Heart disease remains the world’s top killer, and STEMI heart attack survivors face a persistent hidden risk even after successful emergency stent surgery. Reperfusion injury and irreversible left ventricular remodeling create a lifelong burden of heart failure, driven by inflammatory leukotriene chemicals like LTC4 that standard heart medications cannot block.
Montelukast, a decades-old, low-cost asthma pill designed to neutralize leukotriene inflammation, has shown powerful heart-protective effects in preclinical research. The large-scale, triple-blinded Phase 3 trial is now testing whether this repurposed drug can stop permanent heart damage in real anterior STEMI patients treated with emergency stents.
If the trial delivers positive results, cardiologists will gain an accessible, simple new tool to shield millions of heart attack survivors from lifelong heart weakness. Beyond individual patient care, this study stands as a landmark example of drug repurposing: unlocking new life-saving uses for familiar, affordable medicines that already sit on pharmacy shelves across the globe. For anyone who has survived a heart attack, or watched a loved one recover from STEMI, this trial represents tangible hope that the worst long-term consequences of heart damage may one day be preventable with a single daily pill.
As recruitment continues across 12 major Chinese hospitals through early 2027, researchers worldwide await the trial’s six-month cardiac MRI data, ready to reimagine how we treat the millions of severe heart attack patients who rely on emergency stent procedures each year. Sometimes the most revolutionary medical breakthroughs do not come from brand-new lab discoveries—they come from taking a pill we already trust and finding an entirely new way to save lives.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.
The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTreatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial
The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSELUTION 4 De Novo Small Vessel IDE Trial
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a parallel pharmacokinetic (pK) substudy, at up to 80 sites in the US, Canada, Brazil, Japan and Europe. A minimum of 50% of the subjects will be enrolled in the US.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoVideo-based Intervention to Reduce Anxiety in Patients Undergoing Elective PCI
This study aims to evaluate the effectiveness of a video-based educational intervention in reducing anxiety among hospitalised patients scheduled for elective percutaneous coronary intervention (PCI). Participants will be assigned to either a video intervention group or a control group without randomisation. The intervention group will receive a structured educational video related to the PCI procedure, while the control group will receive usual care. Anxiety levels will be measured using the State-Trait Anxiety Inventory at baseline and after the intervention to determine whether the video intervention reduces anxiety before the procedure.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis
Severe aortic stenosis (AS) is often accompanied by coronary artery disease (CAD). While coronary computed tomography angiography (CCTA) is routinely used before aortic valve replacement (AVR) to evaluate coronary anatomy, it lacks physiological assessment of myocardial ischemia. This prospective, single-center, randomized controlled trial aims to evaluate whether integrating functional assessment using CT-derived fractional flow reserve (CT-FFR) with CCTA can optimize revascularization decision-making and improve clinical outcomes. A total of 300 severe AS patients scheduled for transcatheter or surgical AVR will be randomly assigned to either the experimental group (revascularization decisions guided by both CCTA and CT-FFR) or the control group (decisions guided by CCTA alone). Participants will be followed up for 1 year to assess major adverse cardiovascular events and other clinical outcomes.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoIntracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy
The clinical trial is intended to evaluate the efficacy, safety and economic benefit of coronary lithotripsy compared to other additional procedures (cutting or super high pressure balloon angioplasty, ablative procedures) in lesion preparation and interventional treatment of severely calcified coronary stenoses.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEffects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention
Dual Antiplatelet Therapy represents the main therapy for patients presenting with chronic coronary syndromes and undergoing elective PCI. However, most of these patients are not properly covered in terms of inhibition of platelets aggregation at the time of PCI, and are exposed to an higher risk of microvascular damage which in turns might be responsible of residual symptoms persistence and the findings of residual ischemia at the non-invasive tests. In naïve patients, cangrelor can be administered at the time of PCI potentially protecting coronary microcirculation. The aim of this randomized study is indeed to evaluate the use of Cangrelor as compared with standard practice (with Clopidogrel) in terms of incidence of coronary microvascular dysfunction following elective PCI of functionally significant intermediate coronary stenoses. All consecutive patients, fulfilling inclusion and exclusion criteria, will be enrolled and both FFR and CFR/IMR will be measured before and after PCI. Platelet reactivity will be also evaluated mainly during PCI procedure. At 30 days of follow up, patients will be interrogated about symptoms persistence and will be asked to complete the specific Seattle Angina Questionaty (SAQ7). At 3 months a SPECT could be performed in order to evaluate the presence of residual ischemic area in the myocardial territory downstream to the treated vessel. With this study we will be able to evaluate the potential benefit of using Cangrelor, as compared with standard therapy with Clopidogrel, in terms of protection of coronary microcirculation during elective PCI and reduction of both residual symptoms and ischemia at clinical follow up.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoThe FAVOR V AMI Trial
The FAVOR V AMI study is a prospective, multicenter, blinded, randomized, sham-controlled trial comparing the long-term clinical outcomes of the "Functional and Angiography-derived Strain inTegration (FAST)" technique (next-generation quantitative flow ratio \[μQFR\] and radial wall strain \[RWS\]) guided percutaneous coronary intervention (PCI) strategy, with standard treatment strategy, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEffect of Nitrate Supplementation on Blood Pressure and Microvascular Function of Resistant Hypertensive Patients
Arterial hypertension (AH) has been identified as an important public health problem and considered a new epidemic with high mortality and morbidity. High blood pressure (BP) levels increase the chances of coronary artery disease (CAD), heart failure (HF), stroke, chronic renal failure (CRF) and death. Beetroot powder may be an easier way to increase the availability of nitric oxide and consequently vasodilation in these patients. However, studies are needed to evaluate its benefits in patients with AH.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoImplementing Individualized Patient Reported Outcome Measures in Routine Care of Patients With Coronary Artery Disease
Investigators recently developed the APPROACH electronic patient reported outcome (ePROM) Survey and Clinician Report tools to collect individual results from online quality of life and health status surveys for patients with coronary heart disease, and report them back to their treating clinicians. This pilot interventional study uses a pre-post design to assess whether implementing the ePROM system into routine care is feasible and acceptable to patients and physicians, and to inform feasibility for a larger clinical trial. Specifically, the investigators aim to evaluate use of the ePROM Patient Survey and Clinician Report among eligible outpatients with known or suspected coronary artery disease and their cardiologists. Additionally, the investigators aim to determine if the use of the APPROACH ePROMs Clinician Report in routine medical encounters is acceptable (based on administrative burden, ease of use, and time required) to patients and clinicians, and supports effective communication for management of symptoms of coronary artery disease.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoThe Effectiveness of Early Mobilisation on Back Pain in Patients Following Percutaneous Coronary Intervention
Percutaneous Coronary Intervention (PCI) is a common revascularization procedure for patients with coronary artery disease. Patients undergoing PCI are often required to remain in a supine position for several hours after the procedure to prevent complications at the vascular access site. Prolonged immobilization can lead to discomfort and back pain. Early mobilisation may help reduce back pain and improve patient comfort without increasing the risk of complications. This study aims to evaluate the effectiveness of early mobilisation in reducing back pain among patients following Percutaneous Coronary Intervention.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCTO-PCI in Heart Failure Patients
The study investigates wheather CTO-PCI improves survival and heart failure related rehospitalization compared to optimal medical therapy (OMT). This hypothesis will be investigated within a large-scaled international, representative, prospective, randomized, controlled, open-label, event-driven, multicentre trial (trial acronym: CTO – Heart Failure) recruiting patients with planned CTO-PCI.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCoated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease
Although both enteric-coated and plain formulations of aspirin are being used commonly, there are no high-quality comparisons between these formulations with respect to clinical efficacy outcomes in patients with atherosclerotic cardiovascular diseases (ASCVD). Air pollution is also a major contributor to the excess risk of cardiovascular events in many regions of the world. However, little is known about the effect of individual-level mitigation strategies against air pollution in reducing cardiovascular outcomes. The purpose of the first randomization is to compare the efficacy and safety of enteric-coated versus plain low-dose (81 mg) aspirin formulations in a double-blind fashion. The second randomization compares a multifaceted intervention including one-page educational flashcard, cell phone text messages alerting participants on polluted days, recommending them to stay indoors or wear KN-95 facemasks provided by the study team in case of necessary outdoor activity, and recommendation to consume citrus fruits on polluted days versus usual care. Both randomization are powered for clinical outcomes and the results will inform practice.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAssessment of Coronary Artery Disease Before Transcatheter Aortic Valve Replacement: A Randomized, Multicenter, Non-Inferiority Trial
The goal of this clinical trial is to determine whether a non-invasive coronary assessment strategy using photon-counting detector computed tomography (PCD-CT) is non-inferior to invasive coronary angiography (ICA) for evaluating coronary artery disease (CAD) prior to transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCustomizable Respiratory Exercise Device in Individuals Who Have Undergone Cardiac Surgery
The cardiorespiratory system integrates systemic and pulmonary circulation while ensuring adequate oxygenation of the body at rest and during exercise. In addition to chronic respiratory problems that mainly affect the lungs, airways and pulmonary vascular system, respiratory capacity and respiratory muscle strength can be negatively affected in a wide spectrum including cardiac diseases, surgeries, neuromuscular diseases, obesity, long-term bed rest, aging and inactivity. Weakness of the respiratory muscles causes important secondary consequences by causing the increased respiratory demands not to be met during physical activity. It has been reported that respiratory muscle training applied within the scope of pre-operative and post-operative cardiac rehabilitation program is beneficial in terms of increasing respiratory functions, reducing the risk of post-operative complications and length of stay. Respiratory muscle training is known to have many potential beneficial effects on patients undergoing cardiac surgery. Different methods and devices are used to improve and develop the functions of the inspiratory and expiratory muscles and each training method and device has differences. Therefore, it is thought that examining the clinical effects of using a personalized breathing exercise device on respiratory functions, respiratory muscle strength and functional capacity in individuals who have undergone cardiac surgery will contribute to the literature.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoHarmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoThe Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoColchicine Versus Placebo in Acute Myocarditis Patients
Myocarditis is an inflammatory disease of the heart, mostly caused by viruses. Patients with acute myocarditis are exposed to several complications: recurrence, ventricular arrhythmias (from 5 to 30%), heart failure (5-10%), death or heart transplantation (\< 4%). To date, there is no specific treatment for myocarditis. Patient management only focuses upon empirical optimal care of arrhythmia and heart failure. There is a strong rationale for using colchicine in acute myocarditis: * the IL1 (Interleukin1) pathway plays a detrimental role in acute myocarditis. NLRP3 (NOD-like receptor family, pyrin domain containing 3) inflammasome assembly, and subsequent IL-1beta production, are profoundly inhibited by colchicine. * colchicine has been shown to improve cardiac outcomes in inflammatory cardiac disorders, including pericarditis, coronary artery disease, and post pericardiotomy syndrome. * In murine model of CVB3-induced myocarditis (coxsackievirus B3), colchicine improved myocarditis through reduction of NLRP3 activity. * Small case series with improvement of left ejection fraction in myocarditis following low-dose colchicine in addition to conventional heart failure therapy have been reported. With its pleiotropic anti-inflammatory effect in the pro-inflammatory cascade, reducing the myocardial damage and cell death induced during myocarditis, colchicine has the potential to reduce the risk of heart failure and ventricular arrhythmias. Finally, colchicine is a drug widely available, at low cost, and has a long and well-known safety record.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoFexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy
This study evaluates whether fexuprazan is effective in preventing upper gastrointestinal bleeding and related upper gastrointestinal clinical events in high bleeding risk patients who require dual antiplatelet therapy after coronary stent implantation. A total of 400 participants at a single center will be randomly assigned in a 1:1 ratio within 48 hours after stent implantation to receive either fexuprazan 40 milligrams or lansoprazole 30 milligrams once daily for 6 months. The study will compare upper gastrointestinal clinical events during follow-up
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRandomised Trial of Dual Device Treatment Involving Drug-coated Balloon Angioplasty and Drug-eluting Stent Implantation Compared to Single Device Treatments in Patients With Diabetes Mellitus
Purpose of this study: The purpose of the study is to find out whether using a drug coated balloon in combination with a drug-eluting stent is better than the standard practice of using either device on its own. This study is specifically looking at patients with diabetes who have coronary artery disease. This means that their arteries become restricted or blocked, and these restrictions or blockages are called lesions. The study will look at diabetic patients undergoing treatment for lesions in segments of their coronary arteries that have not previously been treated with stents. These are called 'de novo' lesions. The treatment being investigated: In this study, we are comparing two devices, either used together or on their own to treat coronary artery disease. These devices are commercially available in Europe and carry the mark. This study is being carried out to compare the effectiveness of combining the two devices or using them individually: * Pantera® Lux® Paclitaxel Drug Coated Balloon, abbreviated Pantera® Lux® (DCB) A drug coated balloon is a balloon which is covered by an anti-proliferative drug. * Orsiro® biodegradable polymer Sirolimus Eluting Stent Orsiro® (DES) A stent is a short, wire mesh tube that acts like a scaffold to keep your artery open. A drug eluting stent is coated with medication that reduces the risk of the artery becoming blocked again. Both drug-eluting stents and drug-coated balloons are used routinely for the treatment of 'de novo' coronary artery disease in Europe. How will the study be carried out? This study is being conducted in 4 hospitals across Ireland. We aim to recruit 120 participants s in this study. If you agree to participate in this study and sign the informed consent form, you will be asked to participate in the screening process, which will determine if you meet the conditions to participate in the study. You will be "randomised" into one of the 3 study groups. Randomisation means that you are put into a group by chance (similarly to the roll of a dice). Neither you nor your doctor can choose the group you will be in. You will not know which group you were placed in until the end of the study. However, your doctor will know which study group you were placed in. * 40 patients will be treated with Pantera® Lux® (Drug Coated Balloon) only * 40 patients will be treated with Orsiro® (Drug Eluting Stent) only * 40 patients will be treated with a combination of both Pantera® Lux® (Drug Coated Balloon) and Orsiro® (Drug Eluting Stent). If you agree to participate in the study you will be invited to come back for a check-up angiogram 6 months after your procedure to make sure that the treatment has been a success. This is sometimes done in normal clinical practice, but it is not done routinely. You will not be charged for this additional test.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info